June 9, 2013 – Successful Caverstem™ Pilot Study for Treatment of Erectile Dysfunction Using Stem Cell Therapy Published in Peer-Reviewed Literature
Creative Medical Health, Inc. announced that Dr. Joseph Chin, a leading urologist, authored the article; “Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction” in collaboration with two of Creative Medical Health, Inc. co-founders; Dr. Amit Patel and Dr. Thomas Ichim.
The article was published discussing the basis of Creative Medical Health, Inc. procedure for the treatment of erectile dysfunction and results of a trial conducted on a patient in April 2011. This article was published in the Journal of Translational Medicine. Dr. Ichim and Dr. Patel are co-founders of Creative Medical Health, Inc., members of the Company’s Board of Directors and Dr. Ichim is the President of Creative Medical Health, Inc.
A 35 year old patient presented to us with a history of erectile dysfunction unresponsive to oral PDE5 inhibitors (Viagra and Cialis). The patient was a smoker and had a history of hypercholesteremia, marginal effects from intracorporal PGE1 (Caverject) administration, 2 years ago, but as of 6 months, the treatment had no effect. Psychogenic ED was discounted based on 2 independent nocturnal penile tumescence (NPT) tests, which revealed abnormal findings. Upon discussing with his urologist, the patient began seeking penile prosthesis implant. After being explained and understanding the experimental nature of the proposed procedure, the patient signed informed consent. The procedure was approved by the relevant institutional review board. The patient was in otherwise good health.
The patient was administered one tablet of Vocodin (7.5 mg hydrocodone) and one tablet of Xanax (1 mg) 30 minutes before the procedure. Local lidocaine was applied topically at the area of bone marrow puncture. A total of 60 ml of bone marrow aspirate was obtained and processed in a closed-system bone marrow concentration device. Bone marrow mononuclear cells were concentrated to a volume of 2 ml, with 1 ml administered into each cavernousal body using a 25 gauge syringe. A tourniquet was placed around the base of the penis during the injection procedure and held for 5 minutes to allow for maximal retention
No immediate injection-associated adverse events were noted. The patient reported a morning erection 2 days after cell administration. Three weeks after treatment, the patient reported erection strong enough for penetration, but did not have ability to sustain the erection until orgasm. At three month follow-up the patient reported having intercourse until orgasm several times and a marked increase in morning erections. Importantly, no adverse effects or ectopic tissue formation was observed at the 3, 12 and 18 month follow-up. At last visit, 18 months after procedure, the patient still reported improved sexual function as compared to prior to treatment.
About Creative Medical Health, Inc.:
CREATIVE MEDICAL HEALTH, INC., in collaboration with leading U.S. universities, physicians and scientists, has developed and tested our patented treatment of various medical conditions with stem cell technology. Our area of concentration is the scientific and evidence-based approach to the approximately $30 billion per year complementary and alternative medicine market in the United States and $250 billion worldwide market. For more information about Creative Medical Technologies go to www.creativemedicalhealth.com.
Creative Medical Health, Inc.
Tim Warbington, 602-680-7439